(a)For purposes of this section, “narcotic treatment program services” includes, but is not limited to, all of the following:
(1)Admission, physical evaluation, and diagnosis.
(4)Narcotic replacement therapy dosing.
(5)Any medication approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), and all biological products licensed under Section 351 of the Public Health Service Act (42 U.S.C. 262) to treat opioid use disorders. (6)
(A)Intake assessment, treatment planning, and counseling services.
(B)The frequency of counseling, behavioral therapy, or medical
psychotherapy, outcomes, and rates shall be addressed through guidance issued by the department pursuant to subdivision (k). For purposes of this paragraph,
Free access — add to your briefcase to read the full text and ask questions with AI
(a)
For purposes of this section, “narcotic treatment program services” includes, but is not limited to, all of the following:
(1)
Admission, physical evaluation, and diagnosis.
(2)
Drug screening.
(3)
Pregnancy tests.
(4)
Narcotic replacement therapy dosing.
(5)
Any medication approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), and all biological products licensed under Section 351 of the Public Health Service Act (42 U.S.C. 262) to treat opioid use disorders.
(6)
(A)
Intake assessment, treatment planning, and counseling services.
(B)
The frequency of counseling, behavioral therapy, or medical
psychotherapy, outcomes, and rates shall be addressed through guidance issued by the department pursuant to subdivision (k). For purposes of this paragraph, these services include substance use services to pregnant and postpartum Medi-Cal beneficiaries.
(b)
(1)
The department shall establish a narcotic replacement therapy dosing fee for methadone.
(2)
In addition to the narcotic replacement therapy dosing fee specified in paragraph (1), a narcotic treatment program shall be reimbursed for the ingredient costs of methadone dispensed to a Medi-Cal beneficiary. These costs may be determined on an average daily dose of methadone, as set forth by the department.
(c)
Reimbursement for narcotic treatment program services shall be based on a per capita uniform statewide daily reimbursement rate for each individual patient, as established by the department. The uniform statewide daily reimbursement rate for narcotic treatment program services shall be based upon, if available and appropriate, all of the following:
(1)
The outpatient rates for the same or similar services under the fee-for-service Medi-Cal program.
(2)
Cost report data.
(3)
Other data deemed reliable and relevant by the department.
(4)
The rate studies completed pursuant to Section 54 of Chapter 197 of the Statutes of 1996.
(d)
The uniform statewide daily reimbursement rate for ancillary services shall not exceed, for individual services or in the aggregate, the outpatient rates for the same or similar services under
the fee-for-service Medi-Cal program.
(e)
The uniform statewide daily reimbursement rate shall be established after consultation with narcotic treatment program providers and county alcohol and drug program administrators.
(f)
Reimbursement for narcotic treatment program services shall be limited to those services specified in state law and any authorized federally approved Medicaid state plan amendments or waivers related to the Drug Medi-Cal program, and shall be provided in accordance with federal and state law governing the licensing and administration of narcotic treatment programs.
(g)
Reimbursement under this section shall be limited to claims for narcotic treatment program services at the uniform statewide daily reimbursement rate for these services. These rates shall be exempt from the requirements of Section 14021.6.
(h)
(1)
Reimbursement to a narcotic treatment program provider shall be limited to the lower of the uniform statewide daily reimbursement rate, pursuant to subdivision (c), or the provider’s usual and customary charge to the general public for the same or similar service.
(2)
(A)
Reimbursement paid by a county to a narcotic treatment program provider for services provided to any person subject to Section 1210.1 or 3063.1 of the Penal Code, and for which the individual client is not liable to pay, is not a usual and customary charge to the general public for the purposes of this section.
(B)
Subparagraph (A) is not a change in, but is declaratory of, existing law.
(i)
A program shall not be reimbursed for services or medications not rendered to or received by a patient of a narcotic treatment program.
(j)
Reimbursement for narcotic treatment program services shall be administered by the department and any county electing to participate in the program. Utilization and payment for these services shall be subject to federal Medicaid and state utilization and audit requirements.
(k)
Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, may implement, interpret, or make specific this section, in whole or in part, by means of bulletins or similar instructions, until the time that any necessary regulations are adopted.
(
l
)
The department shall adopt regulations necessary to implement this section by July 1, 2023.
(m)
This section shall be implemented to the extent that any necessary federal approval of state plan amendments or other federal approvals, including waivers, are obtained, and federal financial participation is available and not otherwise jeopardized.